EA201890097A1 - Индукция регуляторных т-клеток lamina propria - Google Patents

Индукция регуляторных т-клеток lamina propria

Info

Publication number
EA201890097A1
EA201890097A1 EA201890097A EA201890097A EA201890097A1 EA 201890097 A1 EA201890097 A1 EA 201890097A1 EA 201890097 A EA201890097 A EA 201890097A EA 201890097 A EA201890097 A EA 201890097A EA 201890097 A1 EA201890097 A1 EA 201890097A1
Authority
EA
Eurasian Patent Office
Prior art keywords
regulatory
induction
cells
lamina propria
prevention
Prior art date
Application number
EA201890097A
Other languages
English (en)
Inventor
Эсен Сефик
Наама Джева-Заторски
Кристоф Бенуа
Дэннис Каспер
Дайан Мэтис
Original Assignee
Президент Энд Феллоуз Оф Гарвард Колледж
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоуз Оф Гарвард Колледж filed Critical Президент Энд Феллоуз Оф Гарвард Колледж
Publication of EA201890097A1 publication Critical patent/EA201890097A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Настоящее изобретение относится к способам и композициям для индукции продукции регуляторных Т-клеток и лечения и/или профилактики заболеваний, ассоциированных с патологическими иммунными ответами, таких как воспалительные заболевания кишечника.
EA201890097A 2015-06-22 2016-06-21 Индукция регуляторных т-клеток lamina propria EA201890097A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562183019P 2015-06-22 2015-06-22
US201562183021P 2015-06-22 2015-06-22
PCT/US2016/038502 WO2016209806A1 (en) 2015-06-22 2016-06-21 Induction of lamina propria regulatory t cells

Publications (1)

Publication Number Publication Date
EA201890097A1 true EA201890097A1 (ru) 2018-07-31

Family

ID=57586360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890097A EA201890097A1 (ru) 2015-06-22 2016-06-21 Индукция регуляторных т-клеток lamina propria

Country Status (8)

Country Link
US (1) US20180193391A1 (ru)
EP (1) EP3310367A4 (ru)
JP (1) JP2018519295A (ru)
CN (1) CN108135945A (ru)
BR (1) BR112017028013A2 (ru)
CA (1) CA2990618A1 (ru)
EA (1) EA201890097A1 (ru)
WO (1) WO2016209806A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016278067B2 (en) 2015-06-15 2022-09-22 Cj Bioscience, Inc. Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
KR102205829B1 (ko) * 2017-06-14 2021-01-21 기초과학연구원 신규한 비피도박테리움 비피덤 균주 및 균주 유래 다당체
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3103385A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
KR102269450B1 (ko) * 2018-09-14 2021-06-25 연세대학교 산학협력단 장내 병원성 세균에 대한 항균 활성 균주 및 이를 포함하는 병원성 장내 세균 유발성 질환의 예방 또는 치료용 약학적 조성물
JP2023508138A (ja) * 2019-12-20 2023-03-01 アイカーン スクール オブ メディスン アット マウント サイナイ 炎症性腸疾患を治療するための組成物及び方法
WO2022178292A1 (en) 2021-02-18 2022-08-25 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
EP2125010B1 (en) * 2007-01-25 2014-06-04 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
US20110229498A1 (en) * 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
WO2011151941A1 (ja) * 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US9505798B2 (en) * 2010-11-29 2016-11-29 New York University Steroid compounds as RORyt modulators and uses thereof
WO2012142605A1 (en) * 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
CA2892588A1 (en) * 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
JP2015502410A (ja) * 2011-12-20 2015-01-22 ノース カロライナ ステート ユニバーシティ ポリポーシスおよび結腸直腸癌を低減する方法
EP2682750A1 (en) * 2012-07-02 2014-01-08 Sotio a.s. In vitro method for the diagnosis and surveillance of cancer

Also Published As

Publication number Publication date
EP3310367A4 (en) 2019-02-20
JP2018519295A (ja) 2018-07-19
CN108135945A (zh) 2018-06-08
US20180193391A1 (en) 2018-07-12
BR112017028013A2 (pt) 2018-08-28
CA2990618A1 (en) 2016-12-29
EP3310367A1 (en) 2018-04-25
WO2016209806A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
EA201890097A1 (ru) Индукция регуляторных т-клеток lamina propria
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
CY1122306T1 (el) Συνθεσεις που περιλαμβανουν bakthpiaka στελεχη
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201790413A1 (ru) Антитела против tigit
EA201691940A1 (ru) Новые соединения
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790265A1 (ru) Способы получения тромбоцит-содержащих продуктов
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201691541A1 (ru) Новые анти-baff антитела
EA201890572A1 (ru) Биофармацевтические композиции
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA201791845A1 (ru) Твердые формы менахинолов
EA201691203A1 (ru) Твёрдые формы тенофовира
EA201791389A1 (ru) Способы и композиции антител, направленных против bmp6